Johnson & Johnson – Page 2

J&J’s Subcutaneous Rybrevant Receives CHMP Backing for Lung Cancer Treatment Despite Recent FDA Rejection

9 months ago talkbio0Tagged amivantamab, CHMP, Epidermal Growth Factor Receptor, Johnson & Johnson, Mutation, Non-Small Cell Lung Carcinoma, Rybrevant, subcutaneous formulation, United States Food and Drug Administration

Rybrevant, amivantamab, Johnson & Johnson, CHMP, FDA, subcutaneous formulation, non-small cell lung cancer, EGFR mutations

ICER Report Highlights Unjustified Price Hikes on Five Brand-Name Drugs, Costing U.S. $815 Million in 2023

11 months ago talkbio0Tagged Biktarvy, Cabometyx, CREM gene, Darzalex, drug price, Entresto, Increased, Johnson & Johnson, Novartis, pharmaceutical companies, Prices

ICER, unsupported price increases, drug price hikes, pharmaceutical companies, Gilead Sciences, Johnson & Johnson, Novartis, Biktarvy, Darzalex, Entresto, Cabometyx, Xeljanz.

Eli Lilly and Johnson & Johnson Sue US Government Over 340B Rebate Models

11 months ago talkbio0Tagged Drug Pricing Program, Eli, Eli Lilly, healthcare litigation, HRSA, Johnson & Johnson, pharmaceutical pricing, rebate, Study models

340B Drug Pricing Program, Eli Lilly, Johnson & Johnson, HRSA, rebate models, pharmaceutical pricing, healthcare litigation

TCT 2024: Johnson & Johnson’s Abiomed Successfully Completes Pivotal Study for Innovative Shrinkable Heart Pump, Impella ECP

12 months ago talkbio0Tagged Abiomed, Approved, High-Risk PCI, Impella, Johnson & Johnson, RNASE3 gene, Shock, Cardiogenic, Shrinkable Heart Pump, Thrombin Time Assay, United States Food and Drug Administration

TCT 2024, Johnson & Johnson, Abiomed, Impella ECP, Shrinkable Heart Pump, High-Risk PCI, Cardiogenic Shock, FDA Approval

Starboard Value Targets Kenvue for Revitalization Following $1B Stake in Pfizer

1 year ago talkbio0Tagged activist investor, Consumer, Health, Johnson & Johnson, Kenvue, Pfizer, Pfizer/, Starboard Value

Starboard Value, Kenvue, Johnson & Johnson, Pfizer, activist investor, consumer health, pharmaceuticals

Johnson & Johnson Abandons 340B Rebate Plan Following HRSA Pressure and Congressional Advocacy

1 year ago talkbio0Tagged Dosage Forms, drug discount program, Health Policy, HRSA, Johnson & Johnson, Study models

340B drug discount program, Johnson & Johnson, HRSA, rebate model, healthcare policy, pharmaceutical pricing

Pharmaceutical Giants J&J, Bayer, and Pfizer Announce Layoffs Affecting Nearly 500 Employees

1 year ago talkbio0Tagged Bayer, Biotech Layoffs, Drug Industry, Johnson & Johnson, layoffs, Pfizer

Layoffs, Pharmaceutical Industry, Johnson & Johnson, Bayer, Pfizer, Biotech Layoffs, Workforce Reduction

Big Pharma’s Layoff Wave Continues in New Jersey: J&J and Bayer Announce Significant Job Cuts

1 year ago talkbio0Tagged Bayer, Big Pharma layoffs, Drug Industry, Johnson & Johnson, New Jersey, restructuring

Big Pharma layoffs, New Jersey, Johnson & Johnson, Bayer, pharmaceutical industry restructuring

J&J and Legend’s Carvykti Demonstrates Significant Survival Benefit in Earlier-Line Multiple Myeloma Treatment

1 year ago talkbio0Tagged Benefit, CAR-T, CARTITUDE-4, Carvykti, Continuance of life, Johnson & Johnson, Legend Biotech, Multiple Myeloma, second-line

Carvykti, multiple myeloma, CAR-T therapy, Johnson & Johnson, Legend Biotech, CARTITUDE-4, survival benefit, second-line treatment

SpectraWAVE Secures $50M Series B Funding Led by J&J to Enhance Intravascular Imaging System

1 year ago talkbio0Tagged Coronary Arteriosclerosis, HyperVue Imaging System, Intravascular imaging, Johnson & Johnson, Medical Imaging, Series, SpectraWAVE

SpectraWAVE, Johnson & Johnson, intravascular imaging, HyperVue Imaging System, coronary artery disease, medical imaging, Series B funding